Hemostemix Inc. (HMTXF) Research

Hemostemix Inc. is a biotechnology firm dedicated to the research, development, and commercialization of stem cell therapies derived from blood, aimed at addressing a range of medical conditions. These innovative treatments are uniquely developed from a patient's own blood, providing a non-invasive source of therapeutic cells. Leading their pipeline is ACP-01, an autologous cell therapy currently undergoing Phase II clinical trials in both Canada and the United States. This product targets critical limb ischemia, along with various heart and peripheral arterial diseases. The company is also actively developing other cellular products, including synergistic cell populations and neural cell precursors. Hemostemix Inc. operates from its headquarters in Calgary, Canada.

Market snapshot

Symbol
HMTXF
Price
$0.04
Day change
+0.60%
Market cap
$10.9M
P/E ratio
-2.13x
52-week range
0.035-0.12
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Cell Source, Inc. (CLCS)
  • Devonian Health Group Inc. (DVHGF)
  • HOOKIPA Pharma Inc. (HOOK)
  • EOM Pharmaceuticals Holdings, Inc. (IMUC)
  • Inhibitor Therapeutics, Inc. (INTI)
  • Algorae Pharmaceuticals Limited (LVCLF)
  • Nymox Pharmaceutical Corporation (NYMXF)
  • Oxford BioDynamics Plc (OXBOF)

Open Hemostemix Inc. (HMTXF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.